Nicolas Sidlarewicz

• Turned around the organization and repositioned the company for growth, rebuilding a best-in-class leadership team across Medical, Quality/Regulatory, Commercial and Marketing functions.
• Redefined the go-to-market strategy, driving structural changes in sales organization and elevating medical capabilities.
• Resolved critical market access barriers for two flagship products (new HTA evaluations and derogatory access).
• Delivered a strong growth inflection, scaling revenues from €4.5M (2023) to €23.5M (2025), while materially improving profitability.
• Strengthened governance and compliance frameworks, simplifying processes and ensuring operational excellence.
• Instilled a high-performance culture, centered on accountability, continuous improvement, and cross-functional collaboration.
• Led digital acceleration and AI adoption, embedding data-driven decision-making and productivity gains across the organization.

Set-up from scratch of the French subsidiary of an US biotech company :

• Lead of the French Managing Board
• Legal and Regulatory registration with Health authorities
• Completion of the commercial and medical organization
• Certification of the in-field activities according to the Charter of Ethic
• P&R negotiation
• Full P&L responsibility

• New Business Unit set-up within the company (10 people - medical and commercial).
• Launch of 3 specialized drugs in life-threatening multi-resistant infections.

• Market Access: P&R files application (ASMR3), price negotiation (Liste en sus and Retrocession).
• Business Strategy: Mid and Long run business plan; New products assessments.

• Responsible for overseeing and implementing strategic and operational marketing (18 people).
• Turn-over: 200m€. Marketing investments: 12m€.